Exelixis

Adenosine antagonists market growth driven by R&D in neurodegenerative diseases, oncology, and cardiovascular disorders. Innovations in formulation and delivery systems enhance efficacy and safety, increasing adoption. Key companies include Arcus Biosciences, Corvus Pharmaceuticals, Portage Biotech, Palobiofarm, iTeos Therapeutics. Promising drugs like Etrumadenant, Ciforadenant, PORT-6, and Inupadenant are in various clinical trial phases.

AstraZeneca's Imfinzi sBLA for muscle-invasive bladder cancer (MIBC) receives FDA priority review, with decision expected Q2 2025. Based on phase III NIAGARA study, Imfinzi showed reduced risk of disease progression/recurrence and death in MIBC patients.

Exelixis announced the US FDA will discuss the sNDA for cabozantinib (Cabometyx) for treating advanced pancreatic and extra-pancreatic neuroendocrine tumours at a March 2025 ODAC meeting. The sNDA is based on the phase 3 CABINET trial results, showing cabozantinib's significant improvement in progression-free survival compared to placebo. Cabometyx is approved for various cancers and has received regulatory approvals in over 65 countries.

Investing in biotech ETFs like iShares Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and First Trust NYSE Arca Biotechnology Index Fund (FBT) offers exposure to healthcare innovations. The global biotech market is expected to reach $4.61 trillion by 2034, driven by aging populations and increased healthcare spending. ETFs allow investors to benefit from industry growth while managing risk.

Neuroendocrine Tumors Market to grow at 5.1% CAGR (2020-2034) driven by upcoming therapies, rising incident cases, and increased research. Key players include Novartis, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size in 6MM.

Subscribe to BioWorld™ news services.

Merck & Co. acquires global licensing for LaNova Medicines' PD-1/VEGF bispecific antibody LM-299 for $3.2bn, expanding its oncology pipeline. LM-299, in phase 1 trial in China, shows strong tumor inhibition and is combinable with various therapies.

Ryvu Therapeutics reports Q1-Q3 2024 operating revenues of USD 18.6 million, with accelerated RVU120 Phase II study enrollment due to increased clinical site activation. The company's cash position is USD 58.1 million, providing a runway through Q1 2026. An Investor Event on RVU120 Phase II progress is scheduled for December 12.

AbbVie, a pharmaceutical firm with strong immunology and oncology portfolios, is compared against key competitors in the Biotechnology industry. Analysis reveals AbbVie's PE ratio is low, suggesting potential undervaluation, while its high PB ratio indicates overvaluation based on book value. A low PS ratio implies undervaluation based on sales. AbbVie's high ROE, EBITDA, and gross profit highlight strong profitability and operational efficiency, but low revenue growth indicates challenges in market expansion.

Exelixis reports $539.5M in total revenues, $478.1M from Cabozantinib in the U.S., GAAP EPS of $0.40, and non-GAAP EPS of $0.47. The company updates revenue guidance and announces a favorable patent ruling for Cabozantinib. A collaboration with Merck expands the Zanzalintinib development program. A conference call is scheduled for 5:00 PM Eastern Time.